Literature DB >> 22130573

[Antibiotic dose adjustment in the treatment of MRSA infections in patients with acute renal failure undergoing continuous renal replacement therapies].

Esther Carcelero1, Dolors Soy.   

Abstract

Acute renal failure is frequent in critically ill patients. In those patients who need renal replacement therapy, continuous techniques are an alternative to intermittent haemodialysis. Critically ill patients often have an infection, which can lead to sepsis and renal failure. An early and adequate antibiotic treatment at correct dosage is extremely important. Methicillin resistant Staphylococcus aureus (MRSA) is a frequent nosocomial pathogen that causes a high rate of morbidity and mortality in critically ill patients. Many antibiotics are easily removed by continuous renal replacement therapies (CRRT) leading to a high risk of under dosing and therapeutic failure or resistance breakthrough. The objective of this review is to assess the clinical evidence on the pharmacokinetics and dosage recommendations of the main antibiotic groups used in MRSA treatment in patients treated with CRRT.
Copyright © 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22130573     DOI: 10.1016/j.eimc.2011.09.013

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  2 in total

1.  Optimizing Antimicrobial Dosing for Critically Ill Patients with MRSA Infections: A New Paradigm for Improving Efficacy during Continuous Renal Replacement Therapy.

Authors:  Jiaojiao Chen; Sihan Li; Quanfang Wang; Chuhui Wang; Yulan Qiu; Luting Yang; Ruiying Han; Qian Du; Lei Chen; Yalin Dong; Taotao Wang
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

Review 2.  Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.

Authors:  Marta Ulldemolins; Sergi Vaquer; Mireia Llauradó-Serra; Caridad Pontes; Gonzalo Calvo; Dolors Soy; Ignacio Martín-Loeches
Journal:  Crit Care       Date:  2014-06-23       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.